Sign In
Buy SEER
$1.86
-0.0100 (-0.535%)
At Close: Jun 03, 2026
Seer, Inc. (SEER) Q4 2024 Earnings Call Transcript
10:09pm, Thursday, 27'th Feb 2025
Seer, Inc. (NASDAQ:SEER ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Carrie Mendivil - Investor Relations Omid Farokhzad - Chief Executive Officer and Chair of
Seer, Inc. (SEER) Reports Q4 Loss, Tops Revenue Estimates
07:40pm, Thursday, 27'th Feb 2025
Seer, Inc. (SEER) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.28 per share a year ago.
Seer Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Outlook
04:05pm, Thursday, 27'th Feb 2025
REDWOOD CITY, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial re
Seer to Participate in the TD Cowen 45th Annual Health Care Conference
07:00am, Friday, 21'st Feb 2025
REDWOOD CITY, Calif., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the co
Seer to Feature Proteomic Advancements in Cancer and RNA Therapy Research among other Findings at US HUPO 2025
07:00am, Thursday, 20'th Feb 2025
Seminar from Dr. Jinjun Shi from Brigham and Women's Hospital and Harvard Medical School to highlight study of proteomic perturbations resulting from a novel approach to cancer therapy revealed using
Seer to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025
04:15pm, Thursday, 13'th Feb 2025
REDWOOD CITY, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it wil
Seer to Present at the J.P. Morgan 43rd Annual Healthcare Conference
04:05pm, Thursday, 02'nd Jan 2025
REDWOOD CITY, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the co
SEER commits to an aggressive decarbonization and carbon credit monetization program, starting with its current MV Technology solutions and its planned biocarbon production facilities both domestic an
DevvStream Enters Biogas Market via Partnership with Methane Renewable Energy Leader
07:30am, Thursday, 12'th Dec 2024
Carbon Management Program by SEER and DevvStream will be centered around biogas capture and carbon sequestration through biocarbon, or biochar, production Companies plan to leverage over 150 existing
Seer Ranked Number 57 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™
04:05pm, Thursday, 21'st Nov 2024
Attributes 2,440% revenue growth to increased adoption of its Proteograph™ Product Suite and exciting discoveries made by Seer customers across multiple areas of biology and disease Attributes 2,440
Seer to Participate in Upcoming November Investor Conferences
07:00am, Friday, 08'th Nov 2024
REDWOOD CITY, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced company management
Seer, Inc. (SEER) Q3 2024 Earnings Call Transcript
09:00pm, Wednesday, 06'th Nov 2024
Seer, Inc. (SEER) Q3 2024 Earnings Call Transcript
Seer, Inc. (SEER) Reports Q3 Loss, Tops Revenue Estimates
07:00pm, Wednesday, 06'th Nov 2024
Seer, Inc. (SEER) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.33 per share a year ago.
Seer Enters into a Co-Marketing and Sales Agreement with Thermo Fisher Scientific
04:03pm, Wednesday, 06'th Nov 2024
Collaboration enhances unprecedented access to deep, unbiased proteomics at scale, enabling deeper insights into human biology Collaboration enhances unprecedented access to deep, unbiased proteomics
Seer Highlights Capability of Deep Proteomics to Enhance Genomic Insights Into Alzheimer's, Lung Cancer, and More at ASHG 2024
07:00am, Thursday, 31'st Oct 2024
CoLab session with PrognomiQ and Salk Institute plus multiple presentations of new data offer firsthand look at multi-omic breakthroughs powered by Seer's Proteograph™ Product Suite CoLab session wi
